Thomas Jefferson University

Jefferson Digital Commons
Department of Emergency Medicine Faculty
Papers

Department of Emergency Medicine

7-18-2017

Danshen-Chuanxiong-Honghua Ameliorates Cerebral Impairment
and Improves Spatial Cognitive Deficits after Transient Focal
Ischemia and Identification of Active Compounds.
Xianhua Zhang
Central South University, Changsha, China

Wan Zheng
Nanjing University of Chinese Medicine

Tingrui Wang
Binzhou Medical College

Ping Ren
Nanjing
University
of Chinese
Medicine
Follow this
and additional
works
at: https://jdc.jefferson.edu/emfp

Fushun
Wang
Part of
the Emergency Medicine Commons

Let us know how access to this document benefits you
Nanjing University of Chinese Medicine

See
next page forCitation
additional authors
Recommended

Zhang, Xianhua; Zheng, Wan; Wang, Tingrui; Ren, Ping; Wang, Fushun; Ma, Xin-Liang; Wang, Jian;
and Huang, Xi, "Danshen-Chuanxiong-Honghua Ameliorates Cerebral Impairment and Improves
Spatial Cognitive Deficits after Transient Focal Ischemia and Identification of Active
Compounds." (2017). Department of Emergency Medicine Faculty Papers. Paper 61.
https://jdc.jefferson.edu/emfp/61
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Emergency Medicine Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Xianhua Zhang, Wan Zheng, Tingrui Wang, Ping Ren, Fushun Wang, Xin-Liang Ma, Jian Wang, and Xi
Huang

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/emfp/61

ORIGINAL RESEARCH
published: 18 July 2017
doi: 10.3389/fphar.2017.00452

Danshen-Chuanxiong-Honghua
Ameliorates Cerebral Impairment
and Improves Spatial Cognitive
Deficits after Transient Focal
Ischemia and Identification of Active
Compounds
Xianhua Zhang 1,2 , Wan Zheng 3 , Tingrui Wang 4 , Ping Ren 3 , Fushun Wang 5 , Xinliang Ma 6 ,
Jian Wang 7 and Xi Huang 1,3*
1

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China, 2 Institute of Clinical
Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China, 3 Institute of
TCM-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, China, 4 Department of Neurology,
Binzhou Central Hospital, Binzhou Medical College, Binzhou, China, 5 School of Psychology, Nanjing University of Chinese
Medicine, Nanjing, China, 6 Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA,
United States, 7 Department of Anesthesiology and Critical Care Medicine, School of Medicine, Johns Hopkins University,
Baltimore, MD, United States
Edited by:
Banasri Hazra,
Jadavpur University, India
Reviewed by:
Liang Xiao,
Second Military Medical University,
China
Anita Mukherjee,
University of Calcutta, India
*Correspondence:
Xi Huang
huangx59@163.com
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 29 March 2017
Accepted: 23 June 2017
Published: 18 July 2017
Citation:
Zhang X, Zheng W, Wang T, Ren P,
Wang F, Ma X, Wang J and
Huang X (2017)
Danshen-Chuanxiong-Honghua
Ameliorates Cerebral Impairment
and Improves Spatial Cognitive
Deficits after Transient Focal Ischemia
and Identification of Active
Compounds.
Front. Pharmacol. 8:452.
doi: 10.3389/fphar.2017.00452

Previously, we only apply a traditional Chinese medicine (TCM) Danshen-ChuanxiongHonghua (DCH) for cardioprotection via anti-inflammation in rats of acute myocardial
infarction by occluding coronary artery. Presently, we select not only DCH but also
its main absorbed compound ferulic acid (FA) for cerebra protection via similar action
of mechanism above in animals of the transient middle cerebral artery occlusion
(tMCAO). We investigated whether oral administration of DCH and FA could ameliorate
MCAO-induced brain lesions in animals. By using liquid chromatography-tandem
mass spectrometry (LC-MS/MS), we analyzed four compounds, including tanshinol,
salvianolic acid B, hydroxysafflor yellow A and especially FA as the putative active
components of DCH extract in the plasma, cerebrospinal fluid and injured hippocampus
of rats with MCAO. In our study, it was assumed that FA played a similar neuroprotective
role to DCH. We found that oral pretreatment with DCH (10 or 20 g/kg) and FA
(100 mg/kg) improved neurological function and alleviated the infarct volume as well
as brain edema in a dose-dependent manner. These changes were accompanied
by improved ischemia-induced apoptosis and decreased the inflammatory response.
Additionally, chronic treatment with DCH reversed MCAO-induced spatial cognitive
deficits in a manner associated with enhanced neurogenesis and increased the
expression of brain-derived neurotrophic factor in lesions of the hippocampus. These
findings suggest that DCH has the ability to recover cognitive impairment and
offer neuroprotection against cerebral ischemic injury via inhibiting microenvironmental
inflammation and triggering of neurogenesis in the hippocampus. FA could be one of
the potential active compounds.
Keywords: Danshen-Chuanxiong-Honghua (DCH), cerebral ischemia, inflammation, apoptosis, spatial cognitive
function, neurogenesis
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in rats (Zhang et al., 2017). On this basis, we will further explore
which absorbed bioactive compounds (ABCs) were reached in
injured brain, might be responsible for brain protection following
oral DCH extract. In the current study, we investigated the
neuroprotective effects of DCH pretreatment, with a particular
focus on its anti-apoptotic and anti-inflammatory effects. On this
basis, we also tested the hypothesis that DCH treatment promotes
spatial cognitive function restoration after ischemic stroke by
increasing neurogenesis and the BDNF level in hippocampus. In
the present study, we used the middle cerebral artery occlusion
(MACO) model to investigate the neuroprotective effects of
DCH against acute cerebral ischemia and reperfusion injury in
mice. Meanwhile, the Morris water maze (MWM) was used to
assess the effects of DCH on rat brain function and endogenous
hippocampal and neurogenesis neuroplasticity. As DCH has been
widely used for thousands of years, it is safe and potentially
beneficial for use in treating ischemic stroke.

INTRODUCTION
Despite decades of research, ischemia stroke, which occurs
due to the blood supply to brain becoming blocked, still
remains one of the main causes of permanent disability
and even death (Cheng et al., 2014; Nunez-Figueredo et al.,
2014). Secondary damage from ischemia and reperfusion injury
usually accompanies neuronal dysfunction and cell death,
resulting in cognitive impairments and disability or even death.
Without immediate medical treatment, a cascade of neuronal
cells mostly located in the ischemic penumbra can die and
undergo apoptosis quickly due to free radical overproduction
and massive inflammatory responses (Xiong et al., 2013;
Wang et al., 2017). Pro-inflammatory cytokines, especially IL-1β,
can activate detrimental NF-κB nuclear translocation and
increase p53-upregulated modulators of apoptosis, inducing
neuronal apoptosis and structural brain injury (Shan et al., 2016).
Unfortunately, post-ischemic pro-inflammatory cytokines
including tumor necrosis factor alpha (TNF-α) strongly degrade
the microenvironment of nascent neurons, resulting in diverse
forms of neuronal injury and low survival rates in the dentate
gyrus (DG) of hippocampus (Ahmed et al., 2016). Additionally,
low brain-derived neurotrophic factor (BDNF) protein levels in
the hippocampus may contribute to deteriorative apoptosis of
a subpopulation of hippocampal neurons, decreasing neuronal
survival as well as impairing spatial learning and memory after
cerebral ischemia (Fan et al., 2015; Soares et al., 2017). Despite
advances in revealing the pathophysiology of cerebral ischemia
at the molecular, cellular, and animal levels, the challenge of
finding therapeutic options remains striking due to the serious
side effects of drugs accompanied by a very short therapeutic
window (≤6 h post-stroke) as well as secondary damage from
ischemia and reperfusion injury (Donnan et al., 2008). Therefore,
regulation of this post-ischemic inflammation and BDNF
expression as well as endogenous hippocampal neurogenesis is
a promising potential therapeutic strategy for restoring cognitive
function that is impaired after ischemic insult.
Recently, interest in traditional herbal medicines has been
growing, and traditional herbal medicines have become an
important strategy for new drug development because their
“multi-target” abilities, good synergy and “holistic” approach
are more advantageous compared with “single target-single
compound” approaches (Wang et al., 2012). The traditional
Chinese formula Danshen-Chuanxiong-Honghua (DCH) is
composed of Salvia miltiorrhiza Bge., Ligusticum chuanxiong
Hort. and Carthamus tinctorius L. at a ratio of 2:1:1, which was
optimized by Guanxin II (Huang et al., 2009). Widely used in
Asia, especially in China, DCH is effective for treating ischemic
heart diseases (IHD) (Qin et al., 2009) and providing anti-anginal
effects (Abrams and Thadani, 2005). Meanwhile, it enhances
anti-oxidative and anti-inflammatory responses and the coronary
flow velocity (Qin et al., 2009; Zhang et al., 2010). Our previous
study showed that DCH can prevent acute myocardial infarction
(AMI) in rats by reducing the infarct size and suppressing
myocardial cell apoptosis (Wang et al., 2011). Additionally, our
pharmacokinetic study confirmed that seven compounds were
absorbed into the blood following oral administration of DCH
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MATERIALS AND METHODS
Experimental Animals
All animal experimental procedures were implemented according
to the institutional guidelines of the Animal Care and Use
Committee of Central South University (Changsha, China). The
protocol was approved by the animal experimental committee of
Central South University. All efforts were made to minimize the
pain and suffering of the animals. Male Kunming mice (25–28 g)
and male Sprague-Dawley rats (250–270 g) were purchased from
the Laboratory Animal Centre of Central South University. The
animals were housed at a temperature of 23 ± 2◦ C with a 12/12 h
dark/light cycle and free access to food and water. The animals
were deprived of food for 12 h before the MCAO procedure was
performed.

Reagents
2,3,5-Triphenyltetrazolium chloride (TTC) and 5-bromo-20 deoxyuridine (BrdU) were purchased from Sigma Chemical
Co. Tanshinol, ferulic acid (FA), baicalin, protocatechuic
acid, rosmarinic acid, salvianolic acid B, hydroxysafflor
yellow A and 90 -methyl lithospermate B were purchased
from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai,
China). Rabbit monoclonal Bax antibody (#14796s, 1:1000),
rabbit monoclonal IL-1β antibody (#12426s, 1:1000), rabbit
monoclonal IL-6 antibody (#12912p, 1:1000) were purchased
from Cell Signal Technology. Mouse monoclonal TNF
antibody (#60291-1-Ig, 1:500), rabbit polyclonal BDNF
antibody (#25699-1-AP, 1:200), and mouse β-actin antibody
(#60008-1-Ig, 1:4000) were purchased from Proteintech Group,
Inc., and rabbit polyclonal Bcl-2 antibody (#bs-0032R, 1:100)
was purchased from Bioss (Beijing).

Preparation of DCH Extracts
The dry root and rhizome of S. miltiorrhiza Bge., the dry rhizome
of L. chuanxiong Hort., and the dry flower of C. tinctorius L.
were purchased from the pharmacy of Xiangya Hospital, Central
South University and were authenticated by Professor SY Hu.
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FIGURE 1 | Schematic diagram of the experiment design. Time points represent days after MCAO.

the knot of the Circle of Willis. The suture was gently removed
after 90 min of occlusion to allow reperfusion. An identical
surgery was performed on sham-operated animals, except that
the intraluminal suture was withdrawn immediately to allow
prompt reperfusion. The animals were housed in a warm cage
for approximate 2 h to maintain their body temperature after the
operation. Similarly, the rat preparation of focal cerebral ischemia
was the same as in mice, except that a 4.0 nylon monofilament
suture was inserted into the right MCA and removed after
120 min of occlusion.

The mixture of the DCH formula was soaked in distilled water
(1:12, w/v) and then boiled twice for 30 min at 100◦ C. The twiceboiled blended supernatants were concentrated under pressure at
60◦ C and then lyophilized (yield = 30.53%, w/w), the product of
which was sealed and stored at 4◦ C. The lyophilized powder was
dissolved in saline to 2 g/mL before use.

Experimental Groups and Administration
of Drugs
The design of experiments is divided into two steps, as shown in
Figure 1.
Part 1: DCH lyophilized powder or FA was dissolved with
saline. To assess its preventive role in cerebral ischemia, DCH
extracts (5, 10, and 20 g/kg) and FA (100 mg/kg) were oral
administered once a day for five consecutive days before
ischemia. Sham and vehicle mice were given equal volumes of
saline via the same procedure.
Part 2: Beginning the day after MCAO, DCH extracts
(20 g/kg) and FA (100 mg/kg) were oral administered once a
day for 28 consecutive days. Similarly, sham and vehicle mice
were administered an equal volume of saline via the same
procedure.

Neurological Deficit Assessment
The neurological score was evaluated by an observer blinded
to the animal groups at 24 h after reperfusion as described
previously (Bederson et al., 1986). The neurologic score was
specified as follows: 0, no deficit; 1, flexion of contralateral
forelimb; 2, decrease of resistance toward the contralateral plane;
3, circling monolaterally; 4, unable or difficult to ambulate.

Evaluation of Infarct Volume and
Ipsilateral Edema
After assessment of neurological deficit, mice were killed
by decapitation with anesthesia. The brains were rapidly
removed and frozen at −20◦ C for 10 min and then sliced
into 2-mm-thick coronal sections. The coronal sections were
incubated in 2% TTC in phosphate-buffered saline (pH 7.4)
at 37◦ C for 30 min in the dark and then stored in a 4%
paraformaldehyde solution overnight at room temperature. The
infarct area was morphometrically measured using Image Tool
2.0 software (University of Texas Health Science Center, Texas,
TX, United States). The total infarct volume for each brain
was calculated by adding the lesion areas of all brain sections
(infarct area × thickness [2 mm]) from the same hemisphere.
Correction for ipsilateral edema was accomplished by comparing
the volume of the ipsilateral and contralateral hemispheres as
previously described (Lin et al., 1993). The percentage increase

Preparation of the Focal Cerebral
Ischemia and Reperfusion Model
Transient focal cerebral ischemia was induced by MCAO,
followed by reperfusion as previously reported (Longa et al.,
1989; Zhou et al., 2012) with minor modifications. In brief,
after mice were anesthetized with an intraperitoneal injection
of chloral hydrate (400 mg/kg), a midline neck surgical incision
was made, and the ipsilateral external carotid artery (ECA) was
carefully separated and ligated. A 6.0 nylon monofilament suture
(Beijing Cinontech Co., Ltd, Beijing, China) coated with 1%
poly-L-lysine was inserted from the right common carotid artery
(CCA) to the internal carotid artery (ICA) and gently advanced
to occlude the origin of the middle cerebral artery (MCA) at
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Newborn cells were authenticated by co-labeling with BrdUpositive cells and DAPI. BrdU-positive cells in DG of injured
hemisphere were counted and analyzed in a blinded fashion
in each section under fluorescence confocal microscopy (Leica
SP8, Germany). The results are expressed as the total number
of cells per DG, which was obtained by calculating the total
number of BrdU-positive cells per section and multiplying
by 10.

of the ischemic hemisphere volume was expressed as (ipsilateral
volume – contralateral volume)/contralateral volume × 100%.

Morris Water Maze Test
The Morris water maze is widely used as an assessment of spatial
learning and memory (Morris et al., 1982), and it was applied
in this study from day 24 to 29 after MCAO (Figure 1). In
brief, the water maze device consisted of a circular water tank
(120 cm in diameter and 50 cm in depth) in a dark and quiet
room with several prominent visual cues. The water temperature
was maintained at 25 ± 1◦ C. A black rounded platform (10 cm in
diameter) was submerged 2.0 cm below the surface of the water in
the center of the quadrant and stayed in the same position during
the training period. Rats’ swimming trajectories were recorded by
a video camera with a computer, and the parameters were sent to
an image analyzer.
Each rat was trained twice per day for five consecutive days.
For every trail, the rat was placed into the water facing the
wall of the pool from four starting points in a different order
and allowed to swim. The time to reach the hidden platform
(escape latency) was measured for up to 90 s. If the rat failed,
it would be guided to find the platform and allowed to remain
there for 15 s, and their escape latency was recorded as 90 s.
Finally, 24 h after the last training day, the platform was removed
and the rats were tested on a 90-s retention probe trial. The
number of times the rats crossed the position where the platform
had previously been located was also recorded during the 90-s
trail.

Western Blot Analysis
Mice (part 1: at post-ischemic 24 h) or rats (part 2: at
post-ischemic day 28) were decapitated under anesthesia,
the hippocampus was separated from the lesion hemisphere,
frozen quickly in liquid nitrogen, and stored at −80◦ C. The
hippocampus tissues were disrupted in PBS and homogenized
with RIPA buffer by ice-cold Immune Precipitation Assay and
then centrifuged at 12000 × g for 15 min. Protein samples of
50 µg per lane were separated on polyacrylamide gel and then
transferred onto a polyvinylidene difluoride (PVDF) membrane.
Membranes were blocked with a 5% milk solution (non-fat dry
milk in TBST) for 1 h and then incubated with specific antibodies
as described above at 4◦ C overnight. Following five washes
with TBST for 15 min each, the membranes were incubated
with the corresponding HRP conjugated goat anti-mouse IgG
(1:4000, Proteintech Group) or HRP conjugated goat anti-rabbit
IgG (1:6000, Proteintech Group) for 1 h at room temperature.
Immunoreactivity was detected with a PierceTM ECL substrate
(Thermo) for 3 min, and then, the samples were exposed to X-ray
films. The values were normalized to the intensity levels of β-actin
and analyzed using Quantity-One software (Bio-Rad, Hercules,
CA, United States).

Immunofluorescence
For the cellular proliferation study, BrdU (Sigma), 50 mg/kg in
saline was intraperitoneally injected twice daily at 8-h intervals
on consecutive days (Figure 1). To examine the number of newly
formed cells in the DG of the injured hippocampus, the animals
were perfused transcardially with ice-cold saline, followed by
4% paraformaldehyde in phosphate buffer (PB, 0.1 M, pH 7.4)
12 h after the last BrdU injection (during day 27 and 28 after
MCAO) (Jin et al., 2001). Afterward, the brains were dehydrated
in 30% sucrose in phosphate buffer for 24 h and fixed overnight
in paraformaldehyde for 24 h and then were cryoprotected.
Serial coronal sections (40 µm) were cut on a sliding freezing
microtome (Leica, Germany) and collected in PBS.
Every fifth coronal brain section throughout the
hippocampus, which was 400 µm apart, was selected for
BrdU immunofluorescence staining as previously described
(Yang et al., 2015a). In brief, sections were pretreated with 2
N HCl at 37◦ C for 60 min followed by rinses in 0.1 M borate
buffer for 10 min (pH 8.5). Sections were incubated with
PBS (0.5% Triton X-100, 10% normal goat serum) for 1 h
at room temperature and then incubated in rat monoclonal
anti-BrdU (1:400; Abcam, Cambridge, United Kingdom) at 4◦ C
overnight. After being washed three times with PBS, sections
were incubated for 2 h with FITC conjugated goat anti-rat IgG
(1:200, Proteintech Group, Inc.) at room temperature. Brain
sections were washed again and submerged in DAPI solution
(1:1000) for 10 min, then cover slipped.

Frontiers in Pharmacology | www.frontiersin.org

Preparation of Biological Sample after
Oral Administration of DCH to Rats
Six rats were subjected to MCAO. A small amount of plasma
and CSF was collected at 60 min after oral administration of
DCH extract (20 g/kg) and then sacrificed under anesthesia.
Subsequently, the hippocampus tissue was separated rapidly from
the injured hemispheres on the ice tray and stored at −80◦ C. All
samples (approximately 50.0 mg) were homogenized in 1.5 mL
of ice-cold 0.9% saline, prepared per our previous description.
Briefly, biological sample were extracted separately with ethyl
acetate and methanol using the liquid–liquid extraction (LLE)
method, and the two supernatants were combined and dried
with nitrogen, then reconstituted in 100 µL of 70% methanol
and centrifuged at 13000 rpm for 10 min. A 15 µL aliquot of
the supernatant was injected into the liquid chromatographytandem mass spectrometry (LC-MS/MS) system for qualitative
analysis. Active phytochemicals from the DCH extract in
biological samples were identified by comparing the retention
time in the LC-MS/MS method with an 300SB-C18 column
(4.6 mm × 250 mm, i.d., 5 µm, Agilent, United States)
according to our previous experiment. In brief, HPLC was
performed using an Agilent Technologies 1200 series LC
system (Agilent Corporation, Santa Clara, CA, United States),
and an ABI 3200Q-TRAP quadrupole linear ion trap mass
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FIGURE 2 | Identification of the active compound of DCH extract in the plasma, CSF and injured hippocampus of rats subjected to MCAO. Representative multiple
reaction monitoring (MRM) chromatograms of tanshinol, FA, salvianolic acid B and hydroxysafflor yellow A were exhibited (A). Blank plasma (a); Blank plasma spiked
with the four compounds (b); Plasma sample (c); CSF (d) and injured hippocampal tissue (e) were collected at 0.5 h after a single oral administration of DCH extract
(20 g/kg). The presence of the four compounds in plasma, CSF and hippocampus was showed in bar graphs (B).

by using the regression parameters acquired from the standard
curves.

spectrometer was operated. The mobile phase was composed
of 0.1% formic acid (A) and acetonitrile (B) using a gradient
elution as follows: 15% B from 0 to 3 min; 15–50% B from
3 to 8 min; 50% B from 8 to 10 min; 50–75% B from 10
to 11 min; 75% B from 11 to 14 min; 75–5% B from 14
to 15 min; and 5% B from 15 to 17 min. The flow rate
was set at 1 mL/min, and the injection volume was 15 µL.
The electrospray ion source (ESI) was used in the negative
ion mode, employing MRM with the precursor-to-production
pairs during this experiment. The procedure was controlled by
Analyst 1.4.1 data acquisition and processing software (applied
Biosystems/MDS Sciex).
Reference standard solution of each of the following
compounds was prepared directly in methanol or water:
tanshinol, FA, baicalin, protocatechuic acid, rosmarinic acid,
salvianolic acid B, 90 -methyl lithospermate B, and hydroxysafflor
yellow A. Calibrated standard stock solutions of gradient
concentrations containing the eight constituents were serially
diluted with a mixture of methanol/water (70:30, v/v). The
contents of these components in the DCH extract were calculated

Frontiers in Pharmacology | www.frontiersin.org

Statistical Analysis
All data are presented as the mean ± SEM. The escape latencies
in the Morris water maze test were compared using two-way
analysis of variance (ANOVA) with repeated measure. The other
data were evaluated by one-way ANOVA. Significance levels were
expressed as a value of p < 0.05. Statistical analysis was performed
using GraphPad Prism 5 software.

RESULTS
Chromatographic Analysis of Active
Components in DCH Extracts
To calculate the administered dose, a chromatographic analysis
of DCH extract showed that the concentrations of tanshinol, FA,
baicalin, protocatechuic acid, rosmarinic acid, salvianolic acid
B, 90 -methyl lithospermate B and hydroxysafflor yellow A were
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FIGURE 3 | Preventive effects of oral DCH on brain injury after focal cerebral ischemia in mice. DCH (5, 10, or 20 g/kg) and FA (100 mg/kg) were orally administered
for five consecutive days before inducing brain ischemia. The neurological deficit score (A), infarct volume (B), and ipsilateral edema (C) were determined. (D),
Representative brain coronal sections (2 mm thick) stained with 2% TTC. Typical infarct regions are indicated in white and normal regions are indicated in red. Data
are represented as mean ± SEM, n = 10, ∗ p < 0.05, ∗∗ p < 0.01 versus vehicle group.

FIGURE 4 | Danshen-Chuanxiong-Honghua extract alleviated apoptosis and inhibited pro-inflammatory cytokine production in the injured hippocampus 24 h after
cerebral ischemia and reperfusion. Protein levels of Bax (A), Bcl-2 (B), IL-1β (C), IL-6 (D), and TNF-α (E) were measured by western blot. Quantified results were
normalized to β-actin expression. Data are expressed as mean ± SEM, n = 4, ### p < 0.001, ## p < 0.01 versus sham group; ∗ p < 0.05, ∗∗ p < 0.01 versus vehicle
group.
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FIGURE 5 | Danshen-Chuanxiong-Honghua improved the cognitive deficits induced by ischemic stroke in rats. DCH reversed the prolonged escape latency in
vehicle group (A). The number of crossing was recorded on the 6th day (B). Data were expressed as mean ± SEM, n = 10–13, ## p < 0.01, # p < 0.05 versus sham
group; ∗ p < 0.05 versus vehicle group.

These results suggested that DCH and FA pretreatment improved
the functional outcome after cerebral ischemia and reperfusion
injury (Figure 3). As a control, mice in the sham group did not
show neurological dysfunction or cerebral infarction (data not
shown).

0.743, 0.115, 0.005, 0.011, 0.391, 3.631, 0.009, and 3.109 mg/g,
respectively. Moreover, to explore what active compounds
were absorbed in blood and brain, which exerted potentially
preventative and therapeutic effect on cerebral ischemia, we
qualitatively analyzed using LC/MS-MS. Biological samples of
rats pretreated with DCH extract revealed that four peaks
were present in blood, CSF, and hippocampus of the injured
hemisphere of rats. As shown in Figure 2A, their retention times
were 3.72, 9.66, 8.65, and 4.17 min, respectively. To identify the
active compounds in the biological samples of DCH-pretreated
rats, we performed the ESI and MRM with their precursor-toproduction pairs and compared the retention of the four selective
standards based on our previous study. The four peaks were
tanshinol, salvianolic acid B, FA, and hydroxysafflor yellow A,
which had retention times closest to that of biological samples
of rats. Additionally, FA had the strongest response (Figure 2),
which likely indicates that its concentration is the highest in
target tissue among the four active compounds. Therefore, FA
was selected to test similar preventative effect and underlying
mechanisms of DCH on cerebral ischemia in our study.

DCH Pretreatment Alleviates
Stroke-Induced Inflammatory Reaction
and Apoptosis
We found significantly enhanced protein levels of IL-1β, IL-6,
TNF-α, and Bax, and reduced the levels of Bcl-2 24 h after MACO
in injured hippocampus compared with sham-operated group by
western blot (Figure 4), all which were significantly reversed by
DCH pretreatment (Figure 4). Together, these results showed
that DCH pretreatment mitigated the inflammatory response
and apoptosis in the injured hippocampus of mice. However,
FA pretreatment only ameliorated the levels of inflammatory
cytokines (Figure 4).

DCH Improved Ischemia-Induced Spatial
Cognitive Deficits

DCH Pretreatment Reduces
MCAO-Induced Infarct Mouse Neuronal
Injury

To investigate the effect of chronic DCH and FA treatment
on cognitive function, we exposed the animal to the Morris
water maze test after 28 days of treatment. All rats exhibited a
progressively shorter escape latency in a day-dependent manner
by training every day, and there was a obviously differences
among groups (Figure 5A). Two-way ANOVA showed that,
beginning on day 4, animals in the sham group demonstrated
a shorter latency to finding the platform compared with those
in the vehicle group (p < 0.05), and the results were similar
on day 5 (p < 0.05). These data clearly show the impairment
of memory by experiment-induced focal cerebral ischemia. The
escape latency was greatly decreased on day 4 (p < 0.05) and day 5
(p < 0.05) after DCH treatment. Although it was not statistically
significant, FA treatment also rendered shorter escape latencies
than the vehicle group (p > 0.05). These results indicated that
DCH treatment effectively ameliorated spatial learning through

To assess the potential preventative effects of DCH extract on
mice subjected to MCAO, mice were pretreated with DCH
extract (5, 10, or 20 g/kg/day) for five consecutive days before
the induction of cerebral ischemia. The neurological scores
were evaluated 24 h after MCAO. As shown in Figure 3A, the
neurological scores were significantly attenuated in DCH extract
(10, 20 g/kg)- and FA (100 mg/kg)-pretreated mice compared
with those in a vehicle-treated mice, whereas no significant
neurological dysfunction was observed in the sham group.
Moreover, staining of brain sections with TTC revealed that
pretreatment with DCH extract (10, 20 g/kg) and FA (100 mg/kg)
greatly alleviated the total infarct volume (Figure 3B) and brain
edema (Figure 3C) compared with the vehicle-pretreated group.
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FIGURE 6 | Danshen-Chuanxiong-Honghua increased neurogenesis and the expressions of BDNF. Representative confocal microscopy images were
immunolabeled with BrdU positive cells (green) (A). Quantitative analysis of BrdU positive cells (B). Protein levels of BDNF were measured by western blot (C).
Quantified results were normalized to β-actin expression. Data were represented as mean ± SEM, n = 6–8, ## p < 0.01 versus sham group; ∗∗ p < 0.01, ∗ p < 0.05
versus vehicle group.

5-day training. As shown in Figure 5B, in the probe test without
the platform, vehicle-rats demonstrated a lower the number of
times crossing the platform area compared to rats in the sham
group (p < 0.05). Compared with vehicle group, DCH-treated
rats crossed the platform location more frequently (p < 0.05).
Unfortunately, there was no statistically significant discrepancy
in the FA group (p > 0.05). Therefore, DCH treatment for
28 days obviously improved ischemia-induced spatial memory
impairments (Figure 5).

DISCUSSION
Stroke is a leading factor that is responsible for death and
long-term disability worldwide, imposing a substantial burden
on patients, their relatives, and entire economies (Kim and
Johnston, 2011). In particular, large hemispheric infarctions
commences with the occlusion of the cerebral vasculature and
deprivation of oxygen and nutrient support to specific regions
of the brain, subsequently causing regional brain damage and
functional outcomes that can lead to severe morbidity and
mortality (Ma et al., 2013). Despite the use of thrombolytic drugs
during acute ischemic stroke, narrow therapeutic time-window
and risk of intracranial hemorrhage significantly hamper their
administration in clinic practice (Merino-Zamorano et al., 2015).
Currently, none of available drugs have been shown to be
effective in clinical trials of ischemic stroke (Jin et al., 2013).
Therefore, the search for promising and safe neuroprotective
agents is particularly urgent and important. Here, we find that
DCH usually focuses on a “holistic” approach and multiple
targets to improve the neuroprotective effect and functional
outcomes. As DCH is safe to use based on thousands of
years of experience in East Asia (Qin and Huang, 2009), it
may be a potential therapeutic strategy for ischemia stroke.
A previous study indicated that DCH protects the heart again
oxidative stress, inflammation, and cell apoptosis induced by
acute ischemic myocardial injury in rats (Qin and Huang, 2009).
However, there is no direct evidence proving the neuroprotective
effects of DCH in ischemic stroke.
Strikingly, four components, particularly FA, were
simultaneously absorbed into blood, CSF and hippocampus
of rats subjected to MCAO following oral administration
of DCH extract (Figure 2). Surprisingly, the content of FA
was far lower than that of the other ingredients in DCH

DCH Increased the Neuroproliferation
Ischemic lesions induce neurogenesis in the DG, and newborn
cells reach a peak at post-ischemic day 7 and then die (Yang
et al., 2015b). Interestingly, compared with the sham-operated
group, newborn cells returned to the original standard in the
DG of the damaged hemisphere 28 days after surgery. However,
BrdU positive cells were approximately threefold higher after
DCH treatment on day 28 after MCAO compared with the
vehicle group (p < 0.01, Figures 6A,B). BrdU positive cells
were increased less than twice in the FA group (p > 0.05,
Figures 6A,B). This result indicated that DCH promotes basic
neurogenesis and strengthens inherent neurogenic processes.

DCH Pretreatment Increases Expression
of BDNF Protein
Brain-derived neurotrophic factor is used as a indicator of
neuroplasticity and considered to be involved in neurogenesis.
As shown in Figure 6C, expression of BDNF protein was found
to be markedly decreased in the lesions hippocampus on day 28
after MCAO compared with the sham group. Oppositely, DCH
treatment greatly increased the BDNF level compared with the
vehicle group.
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the mitochondria. Oppositely, Bcl-2 inhibits the apoptosis and
neuronal death (Deng et al., 2017). In addition, a few studies
have reported that pro-inflammatory cytokines induce NF-κB
nuclear translocation and enhancing P53-upregulated modulator
of apoptosis (PUMA); then, p53 is released from Bcl-XL by
activated PUMA, which induces Bax activation and results in
apoptosis within the infarcted hemisphere, ultimately leading
to irreversible brain insult (Shan et al., 2016). In line with these
previous studies, our results suggested that the protective effect of
DCH against neuronal apoptosis was associated with inhibiting
inflammatory responses, which decreased the secretion of IL-1β,
IL-6, and TNF-α, leading to downregulation of Bax and the
upregulation of Bcl-2 in the hippocampus of mice in the acute
phase of ischemic stroke (Figure 4).
In addition to its acute neuroprotective effects on reducing
infarct size, secretion of inflammatory cytokines, and inhibition
of apoptosis, we also investigated the robust neuroprotective
effects of DCH during the chronic phase of stroke subjected to
transient MCAO. The impairment of spatial memory tasks is
generally considered to be induced by ischemia and reperfusion
insults in the hippocampus (Yang et al., 2015a), and we thereby
used the MWM to survey cognitive deficits. Interestingly,
our results demonstrated that DCH-treatment for 4 weeks
significantly reduced the escape latency during the training
compared with that of vehicle treatment, suggesting that DCH
decreased the ischemia-induced spatial learning deficits. In the
same way, DCH also attenuated the spatial memory deficits,
which were exposed by the time spent in the target quadrant
and the number of rats crossing the platform position in the
probe trail. These results indicated that DCH treatment for
4 weeks alleviated learning and memory impairment induced by
MCAO.
The course of learning and memory is closely relevant to the
hippocampus (Yang et al., 2015a). Thus, delayed neuronal death
in the hippocampus induced by MCAO results in neurological
deficits, such as cognitive impairment. In the present study,
we examined the effects of DCH treatment for 4 weeks on
the recovery phase of cerebral ischemia, especially hippocampal
neurogenesis. Previous studies have suggested that the cerebral
ischemia-induced neurogenesis was increased in the rodent
subgranular zone (SGZ) of DG of the injured hemisphere in
adult rodents (Kang et al., 2013; Yang et al., 2015a). Hippocampal
neurogenesis exerts a crucial role in functional outcome and
promotes spatial memory recovery (Liu et al., 2007). Therefore,
long-lasting promotion of neurogenesis in the hippocampus after
a stroke might be a new strategy for the alleviation of post-stroke
cognitive impairment. BrdU, a thymidine analog, is incorporated
into cellular DNA during the S phase of cell proliferation
and thus has been widely used to examine cell proliferation
(Yang et al., 2015b). Here, we found that DCH treatment for
4 weeks significantly increased the number of Brdu positive cells
in the DG after MCAO, indicating that DCH might improve the
proliferation of stroke-induced newborn cells, and the majority
of these newborn cells matured into neurons in the DG. Mature
hippocampal neurons are involved in learning and long-term
memory formation (Suarez-Pereira et al., 2015). Thus, our results
indicate hippocampal neurogenesis may play a beneficial role

extract, but its peak area was approximately threefold stronger
compared with the other in the target tissue (Figure 2B). It
seems to confirm that FA has great oral absorption capacity
and blood-brain barrier permeability, attributed to its favorable
physicochemical properties. Intriguingly, it is reported that
FA plays a neuroprotective role against oxidative Neuro-2a
cells, possibly by inhibiting hydrogen peroxide induced
oxidative stress and down-regulating nNOS, COX-2, and IL-1
(Dong et al., 2015). It also can prevent neuronal cell death against
cerebral ischemic injury, thought the MEK/ERK/p90RSK/Bad
signaling pathway (Koh, 2015). Therefore, these findings support
the possibility that FA is the main active component of DCH,
which is representative of its multiple biomechanism. In our
study, DCH and FA pretreatment decreased neurologic deficit
and the cerebral injury volume (Figure 3) as well as reduced the
protein levels of IL-1β, IL-6, and TNF-α in the hippocampus of
the injured hemisphere after MCAO (Figure 4). Simultaneously,
DCH pretreatment also suppressed ischemia-induced apoptosis
possibly through inhibition of inflammatory responses due to
reduced secretion of IL-1β, IL-6, and TNF-α (Figure 4). In
addition, the results indicated that DCH treatment for 28 days
improved cognitive function by promoting neurogenesis and
expression of BDNF protein in DG after cerebral ischemia and
reperfusion (Figures 5, 6). It was further demonstrated that FA is
the active compound of DCH and exerts similar neuroprotective
effects and is part of the underlying mechanism of the effect of
DCH on ischemic stroke.
Inflammation has been increasingly considered to play
a critical role in the pathophysiology of post-stroke lesions
(Liesz and Kleinschnitz, 2015). During acute ischemic
stroke, sterile inflammation induces the generation of
pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α,
which successively accelerate the neuroinflammatory response
(Barrington et al., 2017). Ischemic injury induces neuronal
death and the release of damage associated molecular patterns
(DAMPs). The pro-inflammatory cytokines IL-1β and TNF-α
have been implicated as key contributors to ischemic stroke
and reperfusion (Murray et al., 2015). IL-6, a multifunctional
cytokine, has an excessive inflammatory response, which might
augment injury due to acute ischemic stroke (Jin et al., 2013;
Yang et al., 2016). Furthermore, previous studies have exhibited
that brain IL-1β and TNF-α levels increase within a few hours
and peak at 24 h after MCAO (Jin et al., 2013), whereas IL-6
concentrations increase from 24 h up to 7 days. Here, these
pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were
chosen as markers to evaluate the inhibition of the inflammatory
response at 24 h after cerebral ischemia and reperfusion in
the hippocampus. All of the above evidence demonstrates
that elevated levels of IL-1β, IL-6, and TNF-α may play a
critical role in inflammation-induced neuronal death after
acute stroke. Interestingly, our findings indicate that DCH
pretreatment inhibits inflammatory responses and improve
neuronal repair by reducing the secretion IL-1β and IL-6 as
well as TNF-α in acute ischemic stroke (Figure 4). As we all
know, apoptosis is another pivotal role in the survival of cells
after ischemic damage (Pan et al., 2016). Bax, an accelerator
of apoptosis, is activated by releasing of cytochrome C from
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in DCH-induced spatial cognitive amelioration after ischemic
stroke.
To further study the mechanism of DCH on enhancing
cognitive outcomes and hippocampal neurogenesis, we analyzed
the levels of pro-inflammatory cytokines as well as BDNF
protein in the ischemic hippocampus after DCH pre-treatment or
treatment. Neuroinflammation begins to disrupt the regulation
of neurogenesis, causing irreversible damage to neurons in
the ischemic core, even in the ischemic penumbra after
ischemic stroke (Liu et al., 2007; Chapman et al., 2015).
Accumulation of pro-inflammatory cytokines immensely alters
the microenvironment of the neural stem cells, which is
deleterious to progenitor survival and proliferation (Das and
Basu, 2008; Ahmed et al., 2016). In support of this notion,
this neuroinflammation-induced unfavorable microenvironment
was reversed by DCH treatment, contributing to the promotion
of neurogenesis after ischemic stroke. We found that the
plentiful secretion of pro-inflammatory cytokines, including
IL-1β, IL-6, and TNF-α caused by ischemic and reperfusion was
significantly inhibited by DCH pretreatment. Taken together,
the mechanism of DCH-increased proliferation of newborn cells
is, in part, associated with its anti-inflammatory effects after
stroke. BDNF is an crucial neurotrophin factor that is involved
in memory formation and storage (Bekinschtein et al., 2007).
As a modulator of neurogenesis, BDNF plays important roles
in neurogenesis and neuroplasticity, as well as in the self-rescue
of different types of neurons after ischemic stroke (Pang et al.,
2004; Venna et al., 2014). Additionally, BDNF also improves
neurogenesis and accelerates the migration of new neurons in
the DG (Schabitz et al., 2007). Here, our results suggested that
BDNF levels in the hippocampus were markedly enhanced by
DCH treatment. In view of the role of BDNF in neurogenesis
and neuroplasticity and that DCH increases the expression
of BDNF, we conclude that DCH treatment might depend

on upregulating BDNF expression to facilitate hippocampal
neurogenesis.
In summary, with anti-inflammatory, anti-apoptotic and
neuroprotective effects, DCH might represent a promising
prevention and therapy for ischemic stroke. Moreover, our results
demonstrate that chronic DCH treatment ameliorates spatial
cognitive impairment and promotes neurogenesis as well as
neuroplasticity in the lesions hippocampus. We speculate that the
attenuation of inflammation and enhancement of neuroplasticity
are necessary for the effect of DCH on neurogenesis, resulting
in improving spatial cognitive function after MCAO. The active
component FA via inhibiting inflammation and increasing the
BDNF level (Figures 4, 6) might be, in part, responsible for the
neuroprotective effects of DCH in ischemic stroke.
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